Hosted on MSN3mon
Biogen Sinks. Why A Surprise Boost From Its Alzheimer's Drug Wasn't Enough.
Spinal muscular atrophy drug Spinraza also generated lower-than-expected sales in the September quarter. And Biogen's multiple sclerosis drugs franchise was "also generally soft." "In our view ...
pharmaphorum6d
FDA slaps partial hold on Biogen, InnoCare MS drug
Biogen's efforts to replenish its multiple sclerosis pipeline have suffered a setback, after the FDA placed a clinical hold on a drug candidate it licensed from China's InnoCare last year for $125 ...
Hosted on MSN11mon
Biogen Tumbles as Drug Closeout Costs, Multiple Sclerosis Medicine Sales Weigh on Profit
Biogen's profit and sales missed forecasts on costs related to the closeout of a controversial Alzheimer's treatment and slowing demand for its multiple sclerosis drugs. The biotech firm took a ...
Breaking Down Biogen: 18 Analysts Share Their Views
The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...
pharmaphorum7y
Biogen MS drug hit by EU safety restriction
Biogen’s Zinbryta multiple sclerosis drug has suffered a serious setback after European regulators restricted its use because of liver safety concerns. The European Medicines Agency said its ...
Nature6y
Milestones in multiple sclerosis: Biogen’s commitment to advancing the field
Multiple sclerosis (MS) is an inflammatory autoimmune ... 1 Pegylated IFN β-1a (PLEGRIDY®, Biogen) was US Food and Drug Administration (FDA)– and European Medicines Agency (EMA)–approved ...
Europe to review safety data for Eisai-Biogen Alzheimer's drug
The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...
Seeking Alpha on MSN6d
Biogen, Eisai Alzheimer’s drug review delayed in EU
Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.
Nasdaq1mon
Biogen Stock Declines 21.4% in 3 Months: How to Play the Stock
Sales of Biogen’s key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza are declining due to competitive pressure. Biogen has ...
EU to Weigh New Safety Data on Biogen, Eisai Alzheimer’s Drug
European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...
Seeking Alpha1mon
Biogen Holds On, But Growth Slips Through Its Fingers
Biogen faces significant challenges in Alzheimer's with Leqembi and their MS portfolio is slowly, but surely, collapsing. Skyclarys is a solid drug, but its acquisition was costly and it may not ...
Reuters23d
Biogen Inc
2024 Biogen raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of its multiple sclerosis drugs. Biogen lifts annual profit forecast ...